Project Grant R01MH142410
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Weill Medical College of Cornell University a Project Grant of $582,953 under the Mental Health Research Grants program (CFDA 93.242), effective June 15, 2025, with completion targeted for March 31, 2028. The award funds development and validation of the KrakenEncoder, a computational tool designed to integrate multi-modal connectome data from structural connectivity (SC) and functional connectivity (FC)...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the Regents of the University of Michigan a $3.97 million Project Grant (CFDA 93.242 - Mental Health Research Grants) effective August 1, 2025, through July 31, 2028, to develop a scalable high-plex pipeline for whole-brain proteomics profiling. The project addresses a critical gap in neuroscience research by creating a comprehensive proteomics atlas of the mammalian brain, complementing existing transcriptomics...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $800,667 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on March 10, 2026, with a completion date of December 31, 2030. This award funds research investigating transcriptional control mechanisms regulated by autism-associated H3K9 methylation regulators during human neurogenesis. The project combines targeted protein...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a $1.45M Project Grant under the Mental Health Research Grants program (CFDA 93.242) on April 15, 2025, to develop an engineered bioprinting platform for studying neural migration in brain assembloids. The project, scheduled for completion by February 28, 2030, will deliver a novel magnetic three-dimensional bioprinting technology termed SPOT to enhance the quality,...
- Federal Grant Award Summary New York University School of Medicine received a $1.34 million Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on September 19, 2025, with a completion date of August 31, 2028. The award supports research and development of a novel noninvasive neuroengineering platform utilizing molecularly engineered nanocrystals for precise modulation of neural structures. The research centers...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Child Mind Institute Inc. a $578,500 Mental Health Research Grants (CFDA 93.242) Project Grant effective May 1, 2025, through February 29, 2028. The award supports the development of integrated computational tools designed to link brain microstructure with functional dynamics in human and non-human primates. The project delivers three primary products: (1) an extension of the BrainBuilder tool to...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Feinstein Institutes for Medical Research a Project Grant of $519,558 under the Mental Health Research Grants program (CFDA 93.242), effective June 15, 2025 through April 30, 2030. The research project focuses on identifying and validating cerebellar-cortical circuitry biomarkers as predictive indicators of antipsychotic treatment response in first-episode psychosis patients. The primary deliverables...
- Federal Grant Award Summary Cornell University received a $797,402 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded July 18, 2025, with completion targeted for April 30, 2030. The research project, "Neural Dynamics Underlying Brain State-Dependent Memory Functions," delivers neuroscience research services focused on understanding how the brain consolidates and preserves memories while minimizing...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $2.94 million Cooperative Agreement to the California Institute of Technology under the Mental Health Research Grants program (CFDA 93.242) beginning September 1, 2025, and concluding May 31, 2030. The award supports the development of a comprehensive toolkit of engineered adeno-associated virus (AAV) capsids designed to enable potent and cell type-specific transgene delivery in non-transgenic rodents and...
- Federal Grant Award Summary New York University received a $633,438 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on June 16, 2025, with a completion date of March 31, 2030. The award supports research on data-driven control of primate prefrontal neural activity using patterned microstimulation. The project addresses a critical gap in neuroscience and neuroengineering by developing a data-driven framework for...
The National Institute of Mental Health (NIMH) awarded Weill Medical College of Cornell University a $1.61 million Project Grant under the Mental Health Research Grants program (CFDA 93.242) on March 10, 2026, with completion targeted for November 30, 2028. This award supports the development of an AlphaFold-assisted affinity probe resource platform designed to advance scalable brain protein mapping through improved recombinant antibody tools. The project integrates artificial intelligence (AI)-based protein structure prediction, structural analysis, and antibody validation expertise to analyze antibody sequences and comprehensively characterize recombinant antibody structural properties, including antigen binding sites and affinities across target species. The primary deliverables include an AI-assisted platform for curating and optimizing recombinant antibodies tailored to specific epitopes and cross-species targets, alongside the establishment of reference datasets for brain research applications. Building on validated monoclonal antibody collections from the Brain Initiative Cell Census Network (BICCN) and Brain Initiative (BICAN) efforts, this integrated technical and resource platform will significantly accelerate the conversion and validation of recombinant antibodies while enabling flexible optimization and design capabilities for diverse research applications. The initiative addresses current limitations in efficiently selecting and prioritizing thousands of monoclonal antibody sequences for cost-effective conversion and validation in large tissue volumes such as whole-mouse and human brains.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 3/10/26 |